OUTPATIENT CANCER PATIENTS: THE RELATIONSHIP BETWEEN INFORMATION OVERLOAD, SYMPTOM SEVERITY, AND EMPOWERMENT LEVEL (CANCER PATIENT)

June 18, 2026 updated by: Seyda Can, University of Yalova
Examining the relationship between information load, symptom severity, and empowerment level in outpatient cancer patients is of great importance for developing holistic care plans tailored to the individual needs of patients and for planning supportive interventions in oncology nursing.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients over 18 years of age receiving outpatient chemotherapy treatment

Description

Inclusion Criteria: Eligibility criteria include having a clinical diagnosis of cancer, having received at least one course of outpatient chemotherapy, and being 18 years of age or older.

-

Exclusion Criteria: The criteria for eligibility include having a severe mental disorder that could affect the patient's perception and responses, it being the first day of treatment, and the patient being under 18 years of age.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relationship Between Information Burden, Symptom Management, and Empowerment Levels in Patients Receiving Outpatient Chemotherapy
Time Frame: 01.07.2026-01.20.2026
Evaluated via Cancer Patient Empowerment Scale (40 items, 5-point Likert). Subscales: Personal Power, Social Support, Healthcare, Community. Total score: 40-200. Higher scores indicate higher patient empowerment. Measured via Cancer Information Overload Scale (8 items, 4-point Likert). Total score: 8-32. Higher scores indicate higher cognitive burden. Evaluated via Memorial Symptom Assessment Scale (32 symptoms; GDI, Phys, Psych subscales). Total score (average): 0-4. Higher scores reflect higher symptom distress.
01.07.2026-01.20.2026
Information burden, symptom severity, and reinforcement level in outpatient chemotherapy patients
Time Frame: 01.07.2026--01.10.2026
Evaluated via Cancer Patient Empowerment Scale (40 items, 5-point Likert). Subscales: Personal Power, Social Support, Healthcare, Community. Total score: 40-200. Higher scores indicate higher patient empowerment. Measured via Cancer Information Overload Scale (8 items, 4-point Likert). Total score: 8-32. Higher scores indicate higher cognitive burden. Evaluated via Memorial Symptom Assessment Scale (32 symptoms; GDI, Phys, Psych subscales). Total score (average): 0-4. Higher scores reflect higher symptom distress.
01.07.2026--01.10.2026

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Yalova

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

May 12, 2026

First Submitted That Met QC Criteria

June 18, 2026

First Posted (Actual)

June 25, 2026

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 18, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-125

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared to protect participant confidentiality and privacy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe